Lundbeck/Otsuka move lead 5-HT6 Alzheimer's candidate into Phase III
This article was originally published in Scrip
Building on positive Phase II data released earlier this year, originator Lundbeck and partner Otsuka Pharmaceutical are taking their novel oral 5-HT6 receptor antagonist Lu AE58054 into a large-scale Phase III program for Alzheimer's disease.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context